Crunchbase profile is pretty weird. Says we were a
Post# of 30067
(Total Views: 254)
Posted On: 07/18/2017 11:35:09 AM
.jpg)
Crunchbase profile is pretty weird. Says we were acquired by Avant in May 2016/ Obvi just talking about DX
https://www.crunchbase.com/organization/amara...es#/entity
Venture-Backed, Alumni
Amarantus Bioscience
Amarantus BioSciences is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.
Neurodegenerative diseases such as Parkinson's, ALS and Alzheimer's as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in dire need of treatments that address the region specific apoptosis associated with each disorder.
Amarantus BioSciences intends to advance therapies that will provide patients with safe and effective treatment options and help curb the soaring healthcare costs associated with care of chronic illnesses. The Company is currently focusing on the development of its lead drug candidate AMRS001 for Parkinson's Disease and Cardiac Ischemia.
https://www.crunchbase.com/organization/amara...es#/entity
Venture-Backed, Alumni
Amarantus Bioscience
Amarantus BioSciences is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.
Neurodegenerative diseases such as Parkinson's, ALS and Alzheimer's as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in dire need of treatments that address the region specific apoptosis associated with each disorder.
Amarantus BioSciences intends to advance therapies that will provide patients with safe and effective treatment options and help curb the soaring healthcare costs associated with care of chronic illnesses. The Company is currently focusing on the development of its lead drug candidate AMRS001 for Parkinson's Disease and Cardiac Ischemia.
(1)
(0)